Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022

Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108 adults (≥ 18 years old) who received one dose of MVA-BN after exposure to mpox, 11 (10%) cases of breakth...

Descripción completa

Detalles Bibliográficos
Autores principales: Merad, Yanis, Gaymard, Alexandre, Cotte, Laurent, Perpoint, Thomas, Alfaiate, Dulce, Godinot, Matthieu, Becker, Agathe, Cannesson, Olivier, Batalla, Anne-Sophie, Oria-Yassir, Fatima, Landré, Sophie, Morfin, Florence, Bouscambert, Maude, Valour, Florent, Ader, Florence, Conrad, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808316/
https://www.ncbi.nlm.nih.gov/pubmed/36695469
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.50.2200882
_version_ 1784862915360194560
author Merad, Yanis
Gaymard, Alexandre
Cotte, Laurent
Perpoint, Thomas
Alfaiate, Dulce
Godinot, Matthieu
Becker, Agathe
Cannesson, Olivier
Batalla, Anne-Sophie
Oria-Yassir, Fatima
Landré, Sophie
Morfin, Florence
Bouscambert, Maude
Valour, Florent
Ader, Florence
Conrad, Anne
author_facet Merad, Yanis
Gaymard, Alexandre
Cotte, Laurent
Perpoint, Thomas
Alfaiate, Dulce
Godinot, Matthieu
Becker, Agathe
Cannesson, Olivier
Batalla, Anne-Sophie
Oria-Yassir, Fatima
Landré, Sophie
Morfin, Florence
Bouscambert, Maude
Valour, Florent
Ader, Florence
Conrad, Anne
author_sort Merad, Yanis
collection PubMed
description Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108 adults (≥ 18 years old) who received one dose of MVA-BN after exposure to mpox, 11 (10%) cases of breakthrough mpox were observed. Sexual exposure was associated with the risk of breakthrough mpox (p = 0.0179). Samples taken from vaccinated breakthrough mpox cases had similar rates of infectious virus isolation than unvaccinated mpox cases.
format Online
Article
Text
id pubmed-9808316
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-98083162023-01-04 Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022 Merad, Yanis Gaymard, Alexandre Cotte, Laurent Perpoint, Thomas Alfaiate, Dulce Godinot, Matthieu Becker, Agathe Cannesson, Olivier Batalla, Anne-Sophie Oria-Yassir, Fatima Landré, Sophie Morfin, Florence Bouscambert, Maude Valour, Florent Ader, Florence Conrad, Anne Euro Surveill Rapid Communication Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108 adults (≥ 18 years old) who received one dose of MVA-BN after exposure to mpox, 11 (10%) cases of breakthrough mpox were observed. Sexual exposure was associated with the risk of breakthrough mpox (p = 0.0179). Samples taken from vaccinated breakthrough mpox cases had similar rates of infectious virus isolation than unvaccinated mpox cases. European Centre for Disease Prevention and Control (ECDC) 2022-12-15 /pmc/articles/PMC9808316/ /pubmed/36695469 http://dx.doi.org/10.2807/1560-7917.ES.2022.27.50.2200882 Text en This article is copyright of the authors or their affiliated institutions, 2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Merad, Yanis
Gaymard, Alexandre
Cotte, Laurent
Perpoint, Thomas
Alfaiate, Dulce
Godinot, Matthieu
Becker, Agathe
Cannesson, Olivier
Batalla, Anne-Sophie
Oria-Yassir, Fatima
Landré, Sophie
Morfin, Florence
Bouscambert, Maude
Valour, Florent
Ader, Florence
Conrad, Anne
Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022
title Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022
title_full Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022
title_fullStr Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022
title_full_unstemmed Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022
title_short Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022
title_sort outcomes of post-exposure vaccination by modified vaccinia ankara to prevent mpox (formerly monkeypox): a retrospective observational study in lyon, france, june to august 2022
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808316/
https://www.ncbi.nlm.nih.gov/pubmed/36695469
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.50.2200882
work_keys_str_mv AT meradyanis outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT gaymardalexandre outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT cottelaurent outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT perpointthomas outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT alfaiatedulce outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT godinotmatthieu outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT beckeragathe outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT cannessonolivier outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT batallaannesophie outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT oriayassirfatima outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT landresophie outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT morfinflorence outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT bouscambertmaude outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT valourflorent outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT aderflorence outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022
AT conradanne outcomesofpostexposurevaccinationbymodifiedvacciniaankaratopreventmpoxformerlymonkeypoxaretrospectiveobservationalstudyinlyonfrancejunetoaugust2022

Ejemplares similares